Sidley Austin LLP advises clients across the life sciences sector, including biotech, biopharma, medical device, diagnostics, and pharma companies. The firm handles transactional, regulatory, compliance, and enforcement matters arising throughout the product lifecycle. Sharon Flanagan leads the firm’s global life sciences practice from San Francisco and represents companies in public and private M&A, joint ventures, minority and controlling investments, and securities offerings. Torrey Cope focuses on FDA regulatory matters from Washington, DC, advising pharma, biotech, and medical tech companies on regulatory strategy and product development issues.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Strong knowledge, great availability. lot of experience.’
Key clients
- EpimAb Biotherapeutics
- Supira Medical, Inc.
- Outset Medical, Inc.
- Contego Medical, Inc.
- Morgan Stanley
- Stryker
- Hoffmann-La Roche, Inc.
- DaVita Inc.
- Genentech
- Nektar Therapeutics
Work highlights
Represented Stryker, in its approximately US$4.9 billion acquisition of Inari Medical, Inc.
Representing Roche, in its acquisition of 89bio.
Represented Roche in its approximately US$1.5 billion acquisition of biopharmaceutical company, Poseida Therapeutics, Inc.
Lawyers
Hall of Fame
The lawyers at the very top of the profession, widely known and respected by peers and clients for their longstanding involvement in market-leading work.
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Sharon R. Flanagan
Other key lawyers
Torrey Cope